Home | About | Journals | Submit | Contact Us | Français |

**|**HHS Author Manuscripts**|**PMC2885905

Formats

Article sections

Authors

Related links

Front Biosci (Elite Ed). Author manuscript; available in PMC 2010 June 15.

Published in final edited form as:

PMCID: PMC2885905

NIHMSID: NIHMS200765

Corresponding author: M. Guillaume Wientjes, College of Pharmacy, 500 West 12^{th} Avenue, Columbus, OH 43210. Telephone: (614) 292-4244, Fax: (614) 688-3223, Email: ude.uso@1.sejtneiW

Send reprint request to: M. Guill Wientjes. College of Pharmacy, 500 West 12^{th} Avenue, Columbus, OH 43210. (614) 292-6488 (TEL), (614) 688-3223 (FAX), ude.uso@1.sejtneiw.

The publisher's final edited version of this article is available at Front Biosci (Elite Ed)

See other articles in PMC that cite the published article.

This study was to compare several published methodologies for evaluating the nature of drug-drug combination, i.e., curve-shift analysis, isobologram, combination index, and universal surface response analysis. The comparison used the literature data on the combination of a glycinamide ribonucleotide formyltransferase inhibitor AG2034 and trimetrexate in cultured tumor cells and the published analysis results for the universal surface response method. All four methods provided similar major conclusions: (a) the nature of interaction between AG2034 and trimetrexate depended on the level of folic acid added to the culture medium (i.e., 2.3 or 78 μM), (b) at high folic acid, the interaction was universally synergistic for all tested combination ratios and over the full range of drug effect levels, and (c) at low folic acid, synergism was present but less extensive. Additional information provided by the different methods is as follows. The curve shift analysis enabled the inspection of the experimental data and visual evaluation of the approximate parallelism between the dose response curves. Isobologram analysis provided the range of concentration ratios where maximal synergy was obtained. The combination index analysis readily provided quantitative estimation of the extent of synergy or antagonism. The universal surface response method summarized drug-drug interaction in a single parameter, facilitating comparison of larger arrays of combinations. Only the curve shift analysis and the universal surface response method yielded a statistical estimate of differentiation between synergy, additivity, and antagonism. In summary, curve shift analysis, isobolograms, combination index analysis, and the universal response surface method are useful methods for analyzing drug-drug interaction, and provide complimentary information.

Evaluation of drug-drug interaction is important in all areas of medicine. The nature and the extent of drug interaction are usually determined in in vitro studies. Computational approaches have been used to analyze experimental data for the nature of interaction, i.e., synergistic, additive or antagonistic. In situations where the mechanisms of drug actions and drug-drug interactions are well understood, mechanism-based pharmacodynamic modeling is a valuable tool (1). However, in the more common situations where there are insufficient mechanistic understandings to allow a well defined method, empirical methods based on Loewe additivity can be applied (2–4). The theoretical basis and methods for analyzing drug-drug interaction have been reviewed previously (5, 6).

Loewe additivity has become the basis for the following contemporary methods used to analyze drug-drug interaction. The isobologram analysis (7) evaluates the nature of interaction of two drugs, i.e., drug A and drug B, at a given effect level. Operationally, the concentrations required to produce the given effect (e.g., IC_{50}) are determined for drug A (IC_{x, A}) and drug B (IC_{x, B}) and indicated on the x and y axes of a two-coordinate plot, forming the two points (IC_{x, A}, 0) and (0, IC_{x, B}). The line connecting these two points is the line of additivity. Then, the concentrations of A and B contained in combination that provide the same effect, denoted as (C_{A, x}, C_{B, x}), are placed in the same plot. Synergy, additivity, or antagonism is indicated when (C_{A, x}, C_{B, x}) is located below, on, or above the line, respectively.

Combination index (CI) is calculated by Eq. 1.

$$CI=\frac{{C}_{A,x}}{I{C}_{x,A}}+\frac{{C}_{B,x}}{I{C}_{x,B}}$$

(1)

A CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, respectively.

Our laboratory recently described the curve-shift analysis and proposed the simultaneous use of isobologram, combination index, and curve-shift analyses for the evaluation of interaction in anticancer agents (8). Curve-shift analysis is a two-dimensional graphical data representation that directly compares the concentration-effect curves obtained for each of the dilution series associated with the selected concentration ratios in the typical experimental design. Concentrations of single agents and combinations are normalized to the corresponding IC_{50} equivalents of single agents, as previously introduced (5, 9–11), and analyzed by nonlinear regression using the Hill equation. A leftward shift of combination concentration-effect curves relative to the curves for both of the single agents indicates Loewe synergy and a rightward shift indicates Loewe antagonism. Because of the two-dimensional format, visual inspection of goodness of fit of experimental data points, and of differences in slopes of the family of the dose response curves is facilitated.

We showed that non-linear regression analysis in the fitting of effect data to model equations represented an improvement over the linear regression fitting to transformed equations frequently used for the combination index analysis (8).

An additional analysis method, proposed and applied by Greco et al. (6,12–13), is the “universal response surface method”. This method assumes that the concentration-effect relationship for each drug separately follows the Hill equation and is designed to simultaneously fit all combination data to a single function. The fitting function (Eq. 2) defaults to Loewe additivity when the “synergism-antagonism parameter” α has a value of zero. Deviation from additivity results in a positive fitted value of α for synergistic interaction, and a negative value of α for antagonistic interaction.

$$1=\frac{{C}_{A,E}}{{IC}_{50,A}{(\frac{E}{{E}_{max}-E})}^{1/{n}_{A}}}+\frac{{C}_{B,E}}{{IC}_{50,B}{(\frac{E}{{E}_{max}-E})}^{1/{n}_{B}}}+\alpha \frac{{C}_{A,E}{C}_{B,E}}{{IC}_{50,A}{IC}_{50,B}{(\frac{E}{{E}_{max}-E})}^{1/(2{n}_{A})+1/(2{n}_{B})}}$$

(2)

Considerable debate remains with respect to the method-of-choice for analyzing drug-drug interaction data (14). The goal of the present report is to compare several methods of data analysis. The comparison used the literature data on the combination effect on tumor cell growth of two anti-folate agents, i.e., the dihydrofolate reductase inhibitor trimetrexate and the glycinamide ribonucleotide formyltransferase inhibitor AG2034 (12). The anti-proliferation effects of these agents, alone or in combination, were studied in the presence of low and high concentrations of folic acid to determine the effect of folates on the interaction between the two agents acting through inhibition of different members of the de novo purine and thymidylate synthesis pathways; the results were analyzed using the universal response surface method. The current study compared the results of curve shift analysis, isobolograms and combination index analysis to the results of the universal response surface method.

The experimental data was provided by Dr. William Greco (Roswell Park Cancer Institute, Buffalo, NY) and was previously reported by Faessel et al. (12). In brief, exponentially growing mycoplasma-free HCT-8 human ileocecal adenocarcinoma cells were treated with AG2034 alone, trimetrexate alone, and their combinations, for 96 h. The trimetrexate -to-AG2034 concentration ratios were 1:0.1, 1:0.2, 1:0.5, 1:1.25, 1:2.5, 1:5, 1:10, 1:20, 1:50, 1:125, and 1:250 in the presence of 2.3 μM folic acid, and 1:1, 1:2, 1:5, 1:12.5, 1:25, 1:50, 1:100, 1:200, 1:500, 1:1250, and 1:2500 in the presence of 78 μM folic acid (5 replicates per data point). To examine the effects of folic acid, the culture medium was supplemented with either low or high concentrations of folic acid (i.e., 2.3 or 78 μM).

Drug activity was measured by the sulforhodamine B (SRB) method; the absorbance readings (OD values) were corrected for the reported, extrapolated background reading of 0.133 (12). We usually correct with the asymptotic minimum OD value for each dilution series (8), but deviated slightly from this practice for a more direct comparison with the data analysis presented in Faessel et al. (12), which used a single background value for correction. The deviation was minimal, averaging 0.9 % of the OD reading for control cells. All SRB absorbance readings at zero drug concentration are averaged and the mean is used as OD at control. The drug effect is measured by (OD at control-OD after treatment)/OD at control *100%.

Isobologram, combination index, and curve shift analysis are derivatives of Loewe additivity model (5–6), which is based on the assumption that a drug cannot interact with itself.

The isobologram analysis provides a graphical presentation of the nature of interaction of two drugs, i.e., drug A and drug B (7). First, in a two-coordinate plot with one coordinate representing concentration of drug A and the other representing concentration of drug B, the concentrations of drugs A and B required to produce a defined effect x (e.g., IC_{50, A} and IC_{50, B} when x=50%), when used as single agents, are placed on the x and y-axes, respectively. The line of additivity is constructed by connecting these two points (e.g., (IC_{50, A}, 0) and (0, IC_{50, B}) for a 50% effect isobologram plot). Second, the concentrations of the two drugs used in combination to provide the same effect x (e.g., x=50%), denoted by point (C_{A, x}, C_{B, x}), are placed in the same plot. Synergy, additivity, or antagonism is indicated when this point is located below, on, or above the line, respectively.

Combination index provides a quantitative measure of the extent of drug interaction at a given effect level (5, 6, 15). That is, the combination concentrations of drug A and drug B to produce a effect x, C_{A, x} and C_{B, x}, are normalized by their corresponding concentrations that produces the same effect as a single agent, IC_{x, A} and IC_{x, B}, respectively. The sum of C_{A, x}/IC_{x, A} and C_{B, x}/IC_{x, B} is defined as the combination index at effect x as indicated by Eq. 1. If not available from experimental data, predicted concentrations of C_{A, x} and C_{B, x}, based on regression-derived Hill parameters of the studied combination ratio, were used to calculate combination index at any effect x (8, 15). Therefore, combination index curves can be generated by plotting combination indices against a series of effect levels. It is worth noting that combination index curves generated by Zhao et al (8) did not use the CALCUSYN program made available by Chou and Talalay (15), and instead were obtained by performing data fitting using nonlinear regression without logarithmic transformation.

Curve shift analysis allows simultaneous presentation of the studied concentration-effect curves of singe-agent and combination treatments in a single plot.

Single agent dose-response relationships were analyzed using the Hill equation (Eq. 3).

$$E=Emax\xb7\frac{{C}^{n}}{{IC}_{50}^{n}+{C}^{n}}$$

(3)

Where E is the measured effect; C is the drug concentration; Emax is the full range of drug effect, and was set at 100%; IC_{50} is the drug concentration producing the median effect of 50%; and n is the curve shape parameter describing the steepness of the concentration-effect relationship.

The combination concentrations of drugs were normalized to their respective single agent IC_{50}. Eq. 4 states the IC_{50}-equivalent concentration of Drug A or Drug B, used alone or in combination with each other, required to produce x% effect. Note that for single agent, one of the two terms (C_{A,x} or C_{B,x}) on the right hand side of the equation becomes zero.

$${IC}_{50}\phantom{\rule{0.16667em}{0ex}}\mathit{Equivalent}\phantom{\rule{0.16667em}{0ex}}\mathit{Concentration}=\frac{{C}_{A,x}}{{IC}_{50,A}}+\frac{{C}_{B,x}}{{IC}_{50,B}}$$

(4)

Where IC_{50, X} is the IC_{50} value of drug X. Substituting Eq. 4 into Eq. 3 yielded Eq. 5, which describes the effects of combination therapy as a function of IC_{50}-equivalent concentrations. IC_{50,combo} and n_{combo} are the values for the combination therapy.

$$\mathit{Combination}\phantom{\rule{0.16667em}{0ex}}\mathit{Therapy}\phantom{\rule{0.16667em}{0ex}}\mathit{Effect}=\frac{{E}_{max}{\left(\frac{{C}_{A,x}}{{IC}_{50,A}}+\frac{{C}_{B,x}}{{IC}_{50,B}}\right)}^{{n}_{\mathit{combo}}}}{{\left(\frac{{C}_{A,x}}{{IC}_{50,A}}+\frac{{C}_{B,x}}{{IC}_{50,B}}\right)}^{{n}_{\mathit{combo}}}+{({IC}_{50,\mathit{combo}})}^{{n}_{\mathit{combo}}}}$$

(5)

Plotting the effects of single agents and combinations against IC_{50}-equivalent drug concentrations enables the simultaneous presentation of these concentration-effect curves in a single plot. Due to the normalization, the curves for the single agents will have an IC_{50} value of one “ IC_{50} equivalent”, while synergistic combinations will have a lower IC_{50} value resulting in a leftward shift, and antagonistic combinations will show a rightward shift.

All programming codes and calculations used SAS language and procedures (SAS, Cary, NC). Nonlinear regressions were performed using the SAS/STAT Proc NLIN routine with the unweighted Marquardt iteration method. Graphical presentations were generated by S-plus (Insightful, Seattle, WA).

Figure 1 shows the dose response curves for trimetrexate, AG2034, or their combinations, in the presence of 2.3 or 78 μM folic acid. Table 1 summarizes the nonlinear fitting results.

In general, the plots showed well-spaced concentration points, with several data points near the IC_{50} value. The experimental design used approximately three-fold steps in concentration dilution; this practice provided, in most curves, at least two points in the middle range of approximately 20 to 80% effect. All concentration-effect curves for various trimetrexate and AG2034 combinations were situated close to or to the left of the curves for the two single agents, indicating additivity or synergy. Differences were observed for the curves obtained at low and high folic acid concentrations.

At the high folic acid concentration (78 μM), all concentration-effect curves for the combinations exhibited a strong leftward shift compared to single-agent curves, indicating synergistic interaction between trimetrexate and AG2034. The IC_{50} equivalents for the combinations ranged from 0.1 to 0.72. The corresponding extent of synergy ranged from a 1.5- to 10-fold leftward shift in the concentration-effect curves. The maximal 8- to 10-fold synergy was observed at about 1:50 trimetrexate:AG2034 molar concentration ratio. Note that most of the concentration-effect curves were in parallel, with the exception that AG2034 showed a shallower slope. The analysis of nonparallel curves for drug-drug interaction is considered more challenging compared to parallel curves (4, 5).

At low folic acid concentration (2.3 μM), several differences were observed. First, the IC_{50} values for single agents AG2034 and trimetrexate were about 10 and 100 fold lower compared to their IC_{50} values at high folic acid concentration. Second, not all concentration-time curves for the combinations showed an apparent leftward shift; five of the twelve combinations overlapped with the curves of single agents. This indicates additivity, which is in agreement with the finding that their combination concentrations expressed in IC_{50} equivalents (as calculated by Eq. 4) were not statistically different from 1.0 at 50% effect level (Table 1). A second cluster of six curves showed a shift to the left; the combination concentrations expressed in IC_{50} equivalents were between 0.5 and 0.6 at 50% effect level, indicating a synergy of about two-fold at this level. Finally, one combination (trimetrexate:AG2034 ratio of 1:50) showed the furthest shift to the left, which appeared to be largely the result of a single data point.

In contrast to curve shift analysis which provides the entire spectrum of effect levels, isobologram analysis is typically conducted for single effect levels, e.g., 50% effect level. Figure 2 shows the isobolograms at 50% effect level, and Table 2 summarizes the results. At the high folic acid concentration, the isobologram analysis showed extensive synergy, with the maximum extent of about 10-fold synergy occurring at a fairly broad range of concentration ratios (the median ratio was slightly higher than 1.0).

At the low folic acid concentration, all data points for trimetrexate and AG2034 combinations were below the line of additivity, indicating synergy. Maximal synergy of approximately 2-fold was achieved at a trimetrexate-to-AG2034 IC_{50, equivalent} concentration ratio close to one.

Figure 3 shows the CI values, and Table 3 summarizes the results. At the high folic acid concentration, the CI values were consistently below 1, indicating synergy. CI decreased at increasing effect levels, indicating increasing degree of synergy at higher effect levels. Synergy of greater than 5- fold at the 50% effect level was observed for the curves with trimetrexate:AG2034 concentration ratios of 1:12.5, 1:25, 1:50, 1:100, 1:200, and 1:500 (Table 3).

At the low folic acid concentration, the results were more complex. First, the CI-vs-effect lines showed inconsistent trends. Six of twelve CI-vs-effect lines showed CI values between 0.23 and 0.6 at the 50% effect levels, indicating a 1.7- to 4-fold synergy. The remaining six curves showed higher CI values that at times were close to or greater than 1. Second, very different CI-vs-effect lines were observed for combinations consisting of similar trimetrexate-to-AG2034 concentration ratios. For example, the lines for sequential trimetrexate:AG2034 concentration ratios increasing from 1:0.1 to 1:2.5, showed increasing CI values with increasing effect levels (trimetrexate:AG2034 = 1:0.1, 1:0.2), a horizontal relationship (trimetrexate:AG2034 = 1:0.5), and decreasing CI values with increasing effect (trimetrexate:AG2034 = 1:1.25, 1:2.5). This trend was not easily noted in the curve shift analysis, but was shown previously based on isobologram analysis at effect levels ranging from 0.1 to 0.9 (12). The pattern was described as a highly reproducible “snaking” of the isobolograms around the line of additivity and was observed for several of the combinations.

This was obtained from the previous publication (12). The conclusions were as follows. (a) The combination of trimetrexate and AG2034 showed synergy at high and low folic acid levels; the value for the interaction parameter α was 1.50±0.25 (mean ± SE) at 2.3 μM and 146±20 at 78 μM. (b) The combination consistently showed the highest degree of synergy at high folic acid concentration. (c) The extent of synergy at high folic acid level was significantly higher than at low folic acid level. (d) The extent of synergy was lower at very low and high effect levels compared to medium effect levels. These general findings are consistent with the results of isobologram, combination index and curve-shift analyses.

It is noted that the IC_{50} values for single agents AG2034 and trimetrexate determined using Eq. 3 differed from the values obtained using the universal response surface method by 0–44% (Table 1). This may be due to the different ways of fitting the parameter value, including the manner of background correction for absorbance at infinite drug concentration, the manner of handling control absorbance under drug-free conditions, the manner of weighting, and the fitting of a whole response surface vs fitting of individual single agent curves.

This report compared different methods of evaluating drug-drug interaction, using the published results for the combinations of trimetrexate and AG2034. The results indicate that isobologram, combination index, curve-shift and universal surface response analyses yielded similar conclusions, i.e., (a) the degree of synergistic interaction between AG2034 and trimetrexate depended on the level of folic acid added to the culture medium (i.e., 2.3 or 78 μM) and (b) at the high folic acid level, the interaction was universally synergistic for all tested combination ratios and over the full range of drug effect levels.

It is noted that the four methods offer complimentary information. The curve shift analysis method allows direct inspection of the experimental data, evaluation of whether the selected concentration points were appropriate, and visual inspection of approximate parallelism between the dose response curves. The latter enables an investigator to determine whether equal or dissimilar effects are observed at low and high effect levels. However, the curve shift analysis method is not well suited for evaluating the range of combination ratio values that yield maximal or near maximal synergy. For the latter, the isobologram analysis provides the changes in the extent of interaction as a function of trimetrexate-to-AG2034 concentration ratios; the points that are located furthest away from the line of additivity correspond to the maximal synergy or antagonism. For example, the current example showed the maximal synergy at the concentration ratio of approximately 1:1 expressed in IC_{50} equivalents. On the other hand, the isobologram analysis does not provide the exact extent of synergy, nor statistical differentiation between synergy, additivity, and antagonism.

The combination index analysis provides an easy presentation of quantitative synergy data, with some caveats. The method lends itself well to evaluation of trends between effect levels, such as the increasing extent of synergy with increasing effect level for all combinations at high folic acid concentrations, and the more complex trends at low folic acid concentration. However, as we have shown previously (8), the combination index analysis is highly sensitive to small changes in effect measurements at low and high concentrations (i.e. at low and high effect levels). A further shortcoming is the lack of statistical evaluation of synergy, additivity, or antagonism.

The universal surface model approach provides a single value summarizing the nature of interaction for the totality of data on the combinations. As this method employs a simultaneous fit of all combination data to a single function, it circumvents the interaction analysis at multiple levels of effect (e.g., IC_{10} to IC_{90}), or for multiple (drug A-to-drug B) concentration ratios needed for 2-dimensional models. The method provides the convenience of a single value of α to represent the extent of synergy. An excellent application of this method is in large screening exercises, searching for the most highly synergistic drug combinations, where the single parameter representing synergistic/antagonistic interaction allows the investigator to rank drug combinations from least to most synergistic. The model further provides a statistical indication of deviation from additivity. The method is, however, not suited to scrutinize the synergy of a single combination in detail. A further limitation is that the model equation defining the interaction surface is designed to describe interactions yielding smoothly bowing isobolograms, and is not versatile for evaluating interactions with a more complex pattern, such as the combination of LY231514 with trimetrexate, which shows synergy at certain concentration ratios and antagonism at other ratios (12). Consequently, the value of α is not indicative of the extent of interaction. A final limitation of the universal surface method is that the value of α cannot be easily converted to an estimate of the extent of synergy. In summary, the four methods of synergy evaluation presented here have their utility and limitations, and analysis of synergy by multiple methods is recommended. Further development of methods that allow statistical differentiation between synergy, additivity, and antagonism is warranted.

The authors thank Dr. William R. Greco for providing the original experimental data sed for analysis. This study is supported in part by R01CA97067 and R01CA100922.

- C
_{A,x}and C_{B,x} - concentration of drugs A and B used in a combination that generates x% of the maximal combination effect
- CI
- combination index
- IC
_{x} - drug concentration needed to produce x% of the maximal effect
- SRB
- sulforhodamine B

The publisher’s final edited version of this article is available at Front Biosci.

**Publisher's Disclaimer: **This is an, un-copyedited, author manuscript that has been accepted for publication in the Frontiers in Bioscience. Cite this article as appearing in the Journal of Frontiers in Bioscience. Full citation can be found by searching the Frontiers in Bioscience (http://bioscience.org/search/authors/htm/search.htm) following publication and at PubMed (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search&DB=pubmed) following indexing. This article may not be duplicated or reproduced, other than for personal use or within the rule of “Fair Use of Copyrighted Materials” (section 107, Title 17, U.S. Code) without permission of the copyright holder, the Frontiers in Bioscience. From the time of acceptance following peer review, the full final copy edited article of this manuscript will be made available at http://www.bioscience.org/. The Frontiers in Bioscience disclaims any responsibility or liability for errors or omissions in this version of the un-copyedited manuscript or in any version derived from it by the National Institutes of Health or other parties.

1. Danhof M, de Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol. 2007;47:357–400. [PubMed]

2. Berenbaum MC. The expected effect of a combination of agents: the general solution. J Theor Biol. 1985;114:413–431. [PubMed]

3. Greco WR, Faessel H, Levasseur L. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? J Natl Cancer Inst. 1996;88:699–700. [PubMed]

4. Loewe S, Muchnik H. Effect of combinations: mathematical basis of problem. Arch Exp Pathol Pharmacol. 1926:313–326.

5. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93–141. [PubMed]

6. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47:331–385. [PubMed]

7. Fraser TR. The antagonism between the actions of active substances. Br Med J. 1872:485–487. [PMC free article] [PubMed]

8. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res. 2004;10:7994–8004. [PubMed]

9. Minto CF, Schnider TW, Short TG, Gregg KM, Gentilini A, Shafer SL. Response surface model for anesthetic drug interactions. Anesthesiology. 2000;92:1603–1616. [PubMed]

10. White DB, Slocum HK, Brun Y, Wrzosek C, Greco WR. A new nonlinear mixture response paradigm for the study of synergism: A three drug example. Curr Drug Metabol. 2003;4:399–409. [PubMed]

11. White DB, Faessel HM, Slocum HK, Khinkis L, Greco WR. Nonlinear response surfaces and mixture experiment methodologies applied to the study of synergism. Biometrical J. 2004;46:56–71.

12. Faessel HM, Slocum HK, Jackson RC, Boritzki TJ, Rustum YM, Nair MG, Greco WR. Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res. 1998;58:3036–3050. [PubMed]

13. Greco WR, Park HS, Rustum YM. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1990;50:5318–5327. [PubMed]

14. Chou TC. Letter to the editor: synergy determination issues. J Virology. 2002;76:10577–10578. [PMC free article] [PubMed]

15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. [PubMed]

PubMed Central Canada is a service of the Canadian Institutes of Health Research (CIHR) working in partnership with the National Research Council's national science library in cooperation with the National Center for Biotechnology Information at the U.S. National Library of Medicine(NCBI/NLM). It includes content provided to the PubMed Central International archive by participating publishers. |